iMetabolic Biopharma Receives Second NIH Grant Award For Drug Discovery

iMetabolic Biopharma Corporation (iMBP) is proud to announce that it has been awarded its second Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH). This Phase 1 grant (1R43HL174270) is funded by the National Heart, Lung, and Blood Institute (NHLBI) for the further development of its innovative drug program in the treatment of atherosclerotic cardiovascular disease (ASCVD), the underlying pathogenic driver leading to heart attack and stroke.

Through the deployment of the iPlatform, iMBP has established a pipeline of drug candidates

and is at the forefront of the developing TechBio space. Formulated as a multidomain recombinant fusion protein, this evolution of the iMBP-001 asset line is the output of this AI-driven computational technology, displaying unique advantages for the engineering of enhanced therapeutic specificity and unique mode of action (MOA). This new version of iMBP-001 is an entirely innovative approach to cardiovascular treatment focused on lipoprotein particle reduction.

In a statement by Dr. Urban Kiernan, iMBP Founder and CEO, "We recognized a long time ago that the treatment of CVD is deficient in dealing with the current state of the problem in the wake of an obesity epidemic. Contributing to 1 in 4 deaths here in America and with ~50% of heart attack victims having normal cholesterol levels, the status quo with a cholesterol-lowering centric treatment model is not working. We are extremely excited about the potential value of this therapeutic innovation and this NIH SBIR support."